The first time most people hear the name multiple myeloma, it sounds unfamiliar. Is it a cancer of the bone, or of the blood? Strictly speaking, it is a blood cancer in which plasma cells, the immune cells that make antibodies, multiply abnormally inside the bone marrow. As these cells crowd the marrow, they interfere with normal blood production, and at the same time they release substances that dissolve bone, which is why it is often described as the blood cancer that weakens the bones.
The symptoms begin quietly. The most common signal is a dull ache in the lower back or ribs, sometimes shrugged off as muscle pain until a minor knock cracks a bone. Anemia leaves people tired and short of breath, and abnormal protein can burden the kidneys until their function declines. When calcium in the blood rises, it brings nausea, constipation, and a foggy head. Because these problems appear separately, myeloma is hard to suspect at first.
Diagnosis fits several tests together. Doctors look in the blood and urine for the abnormal protein that plasma cells produce, called M protein, and a marrow biopsy shows directly how far the plasma cells have grown. To this they add imaging that reveals bone damage, such as X-ray, MRI, or PET. No single number decides it; the damage to bone, blood counts, kidneys, and calcium is weighed together to judge whether treatment is needed.
Treatment has changed a great deal. The core is drug therapy that reduces the abnormal plasma cells: proteasome inhibitors (such as bortezomib), immunomodulators (such as lenalidomide), and targeted antibodies aimed at the plasma cell surface (such as daratumumab) are often combined two or three at a time. For a relatively young patient whose body can withstand it, the disease is first pushed down with drugs, then the person's own blood stem cells, collected in advance, are returned after high-dose treatment, in a procedure called autologous stem cell transplant.
Protecting the bone runs alongside this. Patients receive regular injections of agents that slow further dissolving of bone, and areas with severe pain or high fracture risk may be treated with radiation. To protect the kidneys, drinking enough water matters, and pain medicines that strain the kidneys are adjusted with the care team. There are also stretches when the body is vulnerable to infection, so vaccination and hand hygiene are emphasized.
It is still hard to use the word cure lightly with myeloma, yet this is not a disease to despair over. As good drugs keep arriving, more patients keep the disease deeply suppressed and carry on with daily life for years. Tracking M protein levels and the state of the kidneys and bones through regular tests, and reporting any new pain, fatigue, or swelling as it appears, is the most realistic way to keep it stable. What stage your disease is at and which drug combination fits is best confirmed step by step with your hematology team.
This article shares general medical information in plain language and does not replace individual diagnosis or treatment. Please discuss any specific decisions with your own care team.